A Pilot Phase II Trial Of ABI-007 (A Cremophor El-Free, Protein Stabilized, Nanoparticle Paclitaxel) For The Prevention Of Vascular Access Graft Failure In Patients Undergoing Hemodialysis.

Trial Profile

A Pilot Phase II Trial Of ABI-007 (A Cremophor El-Free, Protein Stabilized, Nanoparticle Paclitaxel) For The Prevention Of Vascular Access Graft Failure In Patients Undergoing Hemodialysis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2012

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Mar 2012 Actual patient number is 9 according to ClinicalTrials.gov.
    • 15 Jun 2011 Planned end date (Nov 2007) added as reported by ClinicalTrials.gov.
    • 06 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top